Endocrinología
Transgender healthcare: metabolic outcomes and cardiovascular risk
Glintborg D, Christensen LL, Andersen MS. Transgender healthcare: metabolic outcomes and cardiovascular risk. Diabetologia. 2024 Nov;67(11):2393-2403. doi: 10.1007/s00125-024-06212-6. Epub 2024 Jul 3. PMID: 38958699.
Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study
Masana, Luis et al.
The Lancet Diabetes & Endocrinology, Volume 12, Issue 12, 880 - 889
Evolution of the Primary Aldosteronism Syndrome: Updating the Approach
Anand Vaidya, Robert M Carey
The Journal of Clinical Endocrinology & Metabolism. December 2020
https://doi.org/10.1210/clinem/dgaa606
Management and follow-up strategies for patients with head and neck paraganglioma
European Journal of Endocrinology, Volume 191, Issue 4, October 2024, Pages 389–398, https://doi.org/10.1093/ejendo/lvae113
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
The New England Journal of Medicine
Nov 2023
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
The New England Journal of Medicine
Junio 2024
Magnesium Disorders
The New England Journal of Medicine
Junio 2024
Top